APA (7th ed.) Citation

Szlosarek, P. W., Wimalasingham, A. G., Phillips, M. M., Hall, P. E., Chan, P. Y., Conibear, J., . . . Sheaff, M. (2021). Phase 1, pharmacogenomic, dose‐expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1‐deficient non‐squamous non‐small cell lung cancer. Cancer medicine (Malden, MA), 10(19), 6642-6652. https://doi.org/10.1002/cam4.4196

Chicago Style (17th ed.) Citation

Szlosarek, Peter W., et al. "Phase 1, Pharmacogenomic, Dose‐expansion Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients with ASS1‐deficient Non‐squamous Non‐small Cell Lung Cancer." Cancer Medicine (Malden, MA) 10, no. 19 (2021): 6642-6652. https://doi.org/10.1002/cam4.4196.

MLA (9th ed.) Citation

Szlosarek, Peter W., et al. "Phase 1, Pharmacogenomic, Dose‐expansion Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients with ASS1‐deficient Non‐squamous Non‐small Cell Lung Cancer." Cancer Medicine (Malden, MA), vol. 10, no. 19, 2021, pp. 6642-6652, https://doi.org/10.1002/cam4.4196.